Neurointerventional Device Update: The Burgeoning Stroke Toolbox

The treatment of acute ischemic stroke and brain aneurysms is rapidly evolving. New transcatheter devices and adjuvant imaging promising to improve outcomes and reduce the burden of neurovascular disease. However, to really spur this market, long-term, large-scale clinical trials are needed.

Approximately 795,000 new or recurrent strokes will occur this year in the US – or one every 40 seconds. And, by 2030, an additional four million Americans will have had a stroke, a 24.9% increase in prevalence from 2010, according to the latest American Heart Association (AHA) projections. Stroke is the fourth leading cause of death in the US, killing 200,000 people each year, and a leading cause of serious long-term adult disability, with over seven million people over age 20 living with the consequences of stroke, according to the AHA. Approximately 87% of strokes are ischemic (caused by a blood vessel blockage in the brain), and as of only a decade ago intravenous therapy with the thrombolytic drug tissue plasminogen activator (tPA) was the only real treatment option for these patients. Now however, minimally invasive, neurointerventional procedures are shifting the treatment paradigm – for ischemic stroke as well as brain aneurysms – and have created promising new device markets that are attracting established, acquisition-minded players as well as innovative start-ups. (See Also see "The Neurovascular Market Tilts Toward A Tipping Point " - Scrip, 1 October, 2011..) A number of positive developments in this space were presented at the Society of NeuroInterventional Surgery (SNIS) 9th Annual Meeting, held in July in San Diego, CA, and so far this year two next-generation mechanical clot-retrieval devices have received US Food and Drug Administration (FDA) approval, with other neurointerventional devices debuting internationally.

According to industry players and researchers in this space, neurointerventional devices to directly address blood clots in the brain are on their way to becoming one of the most impactful and high-growth device markets. (See Also see "Neurointerventional Market Shows Strong Growth Potential" - Medtech Insight, 1 May, 2011. and Also see "Stroke Devices: Innovation Drives Growth" - Medtech Insight, 28 March, 2012..) In fact, in a study out of West Virginia University, presented at the SNIS, endovascular therapy (EVT) was associated with significantly better treatment outcomes compared with traditional intravenous tPA (IVT) for patients suffering acute ischemic stroke resulting from blockages in the large, more high-risk vessels of the brain

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By 

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

How Structured Patient Engagement Gives Medtech Companies A Competitive Edge

 

Communication with patients has become a particularly crucial factor for investors, payers, and other healthcare decision-makers in a hostile market environment.